These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 20001451

  • 1. Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden.
    Martikainen JA, Soini E, Paulsson T.
    Curr Med Res Opin; 2010 Feb; 26(2):389-96. PubMed ID: 20001451
    [Abstract] [Full Text] [Related]

  • 2. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A, Jovell AJ, García-Altés A, García-Closas R, Serra-Majem L.
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [Abstract] [Full Text] [Related]

  • 3. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY, Ko SK, Liew D.
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM.
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Nov; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 6. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 7. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
    Hirsch M, O'donnell J, Olsson A.
    Int J Cardiol; 2005 Oct 10; 104(3):251-6. PubMed ID: 16186052
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Bays HE.
    Curr Med Res Opin; 2007 Sep 10; 23(9):2125-33. PubMed ID: 17655813
    [Abstract] [Full Text] [Related]

  • 9. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program.
    Arterioscler Thromb Vasc Biol; 2004 Aug 10; 24(8):e149-61. PubMed ID: 15297292
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
    Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, McDonough KL, Willey VJ.
    Pharmacotherapy; 2006 Apr 10; 26(4):469-78. PubMed ID: 16553504
    [Abstract] [Full Text] [Related]

  • 12. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep 10; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme a reductase inhibitors on attainment of LDL-C goals.
    Bradford WD, Kleit AN, Nietert PJ, Ornstein S.
    Clin Ther; 2006 Dec 10; 28(12):2105-18; discussion 2104. PubMed ID: 17296467
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of lipid-lowering treatment according to lipid level.
    Pilote L, Ho V, Lavoie F, Coupal L, Zowall H, Grover SA.
    Can J Cardiol; 2005 Jun 10; 21(8):681-7. PubMed ID: 16003451
    [Abstract] [Full Text] [Related]

  • 16. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M, O'Donnell JC, Jones P.
    Eur J Cardiovasc Prev Rehabil; 2005 Feb 10; 12(1):18-28. PubMed ID: 15703502
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost of lipid lowering in patients with coronary artery disease by case method learning.
    Kiessling A, Zethraeus N, Henriksson P.
    Int J Technol Assess Health Care; 2005 Feb 10; 21(2):180-6. PubMed ID: 15921057
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.